VialNAD+ & B12 1,000 mg pre-filled pen
Cellular energy
Investigated for redox balance and cellular energy.
- Ships from Canada in 1–2 business days
- Free shipping over $120
Place your order, then send the e-Transfer. We pack it as soon as it arrives.
For research use only. Not for human consumption.
Complete your setup
Pre-filled, with 4 pen needles in the box. Just add wipes.
- Alcohol Wipes
Free · To wipe the pen's rubber seal
Compare. Side by side, from the research.
About NAD+ & B12
NAD+ is a coenzyme central to how cells convert fuel into usable energy. Research examines its role in redox reactions, mitochondrial output, and the repair pathways associated with biological aging.
How it works
- Redox Carrier
- Cycles between oxidized and reduced forms to shuttle electrons through the reactions generating cellular energy.
- Sirtuin Substrate
- Consumed by sirtuin enzymes, linking NAD+ availability to signaling around mitochondrial upkeep and stress response.
What you need
- Alcohol Wipes
- A protocol guide comes with every order
Shipping & payment
- Packed and dispatched within 1–2 business days
- Delivered across Canada in 2–5 business days, tracked
- Temperature-controlled packaging where the product needs it
- Free shipping on orders over $120
- Prices in CAD · pay by Interac e-Transfer
- Format
- Disposable pre-filled pen · 4 pen needles included
- Strength
- 1,000 mg per pre-filled pen
- Storage
- Refrigerate, away from light.
- Route in research
- Subcutaneous
- SKU
- NJB1000DSP
- Purity
- High-performance liquid chromatography (HPLC), by an independent laboratory
- Identity
- Mass spectrometry, on the same batch
- How often
- Every batch
- COA
- The certificate of analysis is matched to the lot code printed on your vial
- Evidence
- Early clinical
Check your lot
Every vial carries a lot code. Enter it, or scan the QR on the label, to see its expiry and certificate of analysis.
Early clinicalNAD+ biology is well characterized in reviews and animal work, and small randomized human trials have examined NAD+-boosting precursors such as NMN, while controlled human data on subcutaneous NAD+ itself remain limited.
What research examines
- Cellular energy metabolism and redox reactions
- Sirtuin activity in aging and disease
- Aging-related metabolic decline and neurodegeneration
- Blood-brain barrier integrity in aging animal models
- Muscle insulin sensitivity in human trials of the precursor NMN
Reported in studies
- Human safety data for subcutaneous NAD+ are limited
- Safety of the precursor NMN has been reviewed across human clinical trials
- A review has raised safety questions about NMN marketed as an anti-aging product
- Adverse events for NAD+ itself are not summarized in the cited studies
Published research protocols
100 mg, 3x/week, am
Research protocols have used 50–200 mg per administration, 3 times per week (morning). Reported cycle: continuous.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
CoreX AI
Ask about NAD+ & B12
Plain answers, from the basics to the studies.
Research information, not medical advice.
Often researched with NAD+ & B12
Vial
Vial
Vial
FAQ
Questions, answered
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in cells that is central to converting nutrients into usable energy. Research examines its role in redox reactions, mitochondrial output, and repair pathways associated with biological aging. It is categorized as a longevity research compound, and reviews have discussed how NAD+ levels relate to aging, metabolism, and neurodegeneration.
NAD+ acts as an electron carrier, cycling between oxidized and reduced forms to shuttle electrons through the reactions that generate cellular energy. It is also a required substrate consumed by sirtuin enzymes, which are studied for metabolic regulation, mitochondrial upkeep, and stress response. This links NAD+ availability to cellular maintenance signaling, a relationship examined in reviews of NAD+ and sirtuins in aging and disease.
Research has studied NAD+ in the context of aging, metabolism, and neurodegeneration, largely through reviews and animal models. One animal study reported that NAD+ addressed aging-induced blood-brain barrier damage via the CX43-PARP1 axis. Human trials have mostly examined NAD+-boosting precursors, including a randomized trial of NMN in healthy middle-aged adults and one reporting increased muscle insulin sensitivity in prediabetic women.
Human safety data for subcutaneous NAD+ are limited, and adverse events for NAD+ itself are not summarized in the cited studies. Much of the available human safety information concerns the precursor NMN, whose safety has been reviewed across clinical trials. At least one review has also discussed both promises and safety concerns of NMN as an anti-aging product, so findings should be interpreted cautiously.
Research protocols have used 50–200 mg per administration, 3 times per week in the morning, delivered subcutaneously, with a continuous reported cycle. These figures describe what protocols have used and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference. Related human trials of NAD+ precursors such as NMN have used oral supplementation rather than direct NAD+ administration.
You may also like
Vial
Vial
Vial
Vial
Vial
Vial